The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)


DESyne novolimus-eluting coronary stent is superior to Endeavor zotarolimus-eluting coronary stent at five-year follow-up: final results of the multicentre EXCELLA II randomised controlled trial

EuroIntervention 2016;12:e1336-e1342 published online ahead of print October 2015 published online e-edition December 2016. DOI: 10.4244/EIJY15M10_04

1. Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands; 2. Academisch Ziekenhuis Middelheim, Antwerp, Belgium; 3. Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil; 4. Auckland City Hospital, Auckland, New Zealand; 5. Cardialysis BV, Rotterdam,

Aims: Newer-generation drug-eluting stents (DES) have been shown to be superior to first-generation DES. Current-generation DES have zotarolimus, everolimus or biolimus as antiproliferati

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction